• SyncroPatch 384/768PE

    APC with highest throughput on the market
  • SyncroPatch 384/768PE

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768PE

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768PE

    True internal perfusion with continuous data acquisition
  • SyncroPatch 384/768PE

    Assay flexibility via high tech

2018 - Expression and pharmacology of GluA2-containing AMPA receptors in cell lines and stem cell-derived neurons

icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE poster, Europhysiology Meeting 2018  logo pdf   (0.9 MB)

 

Abstract:

The vast majority of excitatory neurotransmission is mediated by AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors1. The functional receptor exists as a tetramer, either homomers or heteromers, from a repertoire of 4 different subunits, GluA1 – GluA41. It is well known that glutamate is a neurotoxin and it is proposed that overactivation of ionotropic glutamate receptors may underlie many neurodegenerative disorders such as ischemic stroke, epilepsy, Parkinson’s and dementia2. Enhancement of AMPA receptor activation by, for example, BDNF, has been proposed to have beneficial effects of learning and memory and has potential therapeutic value in the treatment of depression, Huntington’s and Parkinson’s diseases1. We have used GluA2 receptors expressed in HEK cells on 3 different automated patch clamp systems recording from either 1, 8 or 384 wells simultaneously. GluA2 was activated by glutamate, inhibited by CNQX and potentiated by LY404187.

In addition to GluA2 expressed in HEK cells, we also recorded glutamatergic-enriched cortical neurons derived from induced pluripotent stem cells on an automated patch clamp platform. In these neurons we recorded various voltage-gated channels. In addition, glutamate responses were recorded which were potentiated by LY404187.

 

References:

1. Traynelis, S.F., et al. (2010) Pharmacol. Rev. 62: 405-496 

2. Dingledine, R., et al. (1999) Pharmacol. Rev. 51: 7-61 

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok